To prohibit prescription drug companies from compensating other prescription drug companies to delay the entry of a generic drug, biosimilar biological product, or interchangeable biological product into the market.
The bill’s titles are written by its sponsor.
Sponsor and status
Sponsor. Representative for New York's 10th congressional district. Democrat.
Last Updated: Apr 28, 2021
Length: 20 pages
117th Congress (2021–2023)
This bill was introduced on September 29, 2021, in a previous session of Congress, but it did not receive a vote.
Although this bill was not enacted, its provisions could have become law by being included in another bill. It is common for legislative text to be introduced concurrently in multiple bills (called companion bills), re-introduced in subsequent sessions of Congress in new bills, or added to larger bills (sometimes called omnibus bills).
7 Cosponsors (4 Democrats, 3 Republicans)
What stakeholders are saying
Apr 30, 2019
Earlier Version — Ordered Reported
This activity took place on a related bill, H.R. 2375 (116th).
Apr 28, 2021
Bills and resolutions are referred to committees which debate the bill before possibly sending it on to the whole chamber.
Sep 29, 2021
A committee has voted to issue a report to the full chamber recommending that the bill be considered further. Only about 1 in 4 bills are reported out of committee.
H.R. 2891 (117th) was a bill in the United States Congress.
A bill must be passed by both the House and Senate in identical form and then be signed by the President to become law.
Bills numbers restart every two years. That means there are other bills with the number H.R. 2891. This is the one from the 117th Congress.
This bill was introduced in the 117th Congress, which met from Jan 3, 2021 to Jan 3, 2023. Legislation not passed by the end of a Congress is cleared from the books.
How to cite this information.
We recommend the following MLA-formatted citation when using the information you see here in academic work:
GovTrack.us. (2023). H.R. 2891 — 117th Congress: Preserve Access to Affordable Generics and Biosimilars Act. Retrieved from https://www.govtrack.us/congress/bills/117/hr2891
“H.R. 2891 — 117th Congress: Preserve Access to Affordable Generics and Biosimilars Act.” www.GovTrack.us. 2021. March 27, 2023 <https://www.govtrack.us/congress/bills/117/hr2891>
Preserve Access to Affordable Generics and Biosimilars Act, H.R. 2891, 117th Cong. (2021).
|title=H.R. 2891 (117th)
|accessdate=March 27, 2023
|author=117th Congress (2021)
|date=April 28, 2021
|quote=Preserve Access to Affordable Generics and Biosimilars Act
- show another citation format:
- Blue Book
- Wikipedia Template
Where is this information from?
GovTrack automatically collects legislative information from a variety of governmental and non-governmental sources. This page is sourced primarily from Congress.gov, the official portal of the United States Congress. Congress.gov is generally updated one day after events occur, and so legislative activity shown here may be one day behind. Data via the congress project.